{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T03:01:19Z","timestamp":1773889279326,"version":"3.50.1"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2016,1,27]],"date-time":"2016-01-27T00:00:00Z","timestamp":1453852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0148093","type":"journal-article","created":{"date-parts":[[2016,1,27]],"date-time":"2016-01-27T18:56:07Z","timestamp":1453920967000},"page":"e0148093","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells"],"prefix":"10.1371","volume":"11","author":[{"given":"Shuit-Mun","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fu-Hwa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueh-Lun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huei-Mei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,1,27]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1365-2141.2001.02558.x","article-title":"Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory","volume":"113","author":"DT Holyoake","year":"2001","journal-title":"Br J Haematol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.leu.2403241","article-title":"JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis","volume":"18","author":"LS Steelman","year":"2004","journal-title":"Leukemia"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000140633","article-title":"BCR-ABL in chronic myelogenous leukemia-how does it work?","volume":"119","author":"JM Goldman","year":"2008","journal-title":"Acta Haematol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrd2324","article-title":"Flying under the radar: the new wave of BCR-ABL inhibitors","volume":"6","author":"A Quintas-Cardama","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1756-8722-3-47","article-title":"First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib","volume":"3","author":"G Wei","year":"2010","journal-title":"J Hematol Oncol"},{"issue":"Suppl 2","key":"ref6","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1007\/s00277-015-2321-3","article-title":"The choice of first-line chronic myelogenous leukemia treatment","volume":"94","author":"C Fava","year":"2015","journal-title":"Ann Hematol"},{"issue":"Suppl 2","key":"ref7","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1007\/s00277-015-2322-2","article-title":"A review of the European LeukemiaNet recommendations for the management of CML","volume":"94","author":"M Baccarani","year":"2015","journal-title":"Ann Hematol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10147-013-0641-7","article-title":"Ever-advancing chronic myeloid leukemia treatment","volume":"19","author":"S Kimura","year":"2014","journal-title":"Int J Clin Oncol"},{"key":"ref9","first-page":"253","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"MA Jordan","year":"2004","journal-title":"Nature"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrd3253","article-title":"Microtubule-binding agents: a dynamic field of cancer therapeutics","volume":"9","author":"C Dumontet","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000351852","article-title":"MPT0B169, a new tubulin inhibitor, inhibits cell growth and induces G2\/M arrest in nonresistant and paclitaxel-resistant cancer cells","volume":"92","author":"WH Lee","year":"2013","journal-title":"Pharmacology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e61939","DOI":"10.1371\/journal.pone.0061939","article-title":"Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation","volume":"17","author":"YL Lee","year":"2013","journal-title":"PLoS One"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.bbrc.2004.06.083","article-title":"Basic fibroblast growth factor antagonizes activin A-mediated growth inhibition and hemoglobin synthesis in K562 cells by activating ERK1\/2 and deactivating p38 MAP kinase","volume":"320","author":"HM Huang","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"C407","DOI":"10.1152\/ajpcell.00312.2013","article-title":"Interferon-\u03b3 suppresses activin A\/NF-E2 induction of erythroid gene expression through the NF-\u03baB\/c-Jun pathway","volume":"306","author":"WH Lee","year":"2014","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of BCRABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with Philadelphia chromosome","volume":"344","author":"BJ Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"e6124","DOI":"10.1371\/journal.pone.0006124","article-title":"ERK2 but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy","volume":"4","author":"CI Aceves-Luquero","year":"2009","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1038\/sj.onc.1206948","article-title":"P-glycoprotein: from genomics to mechanism","volume":"22","author":"SV Ambudkar","year":"2003","journal-title":"Oncogene"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"FX Mahon","year":"2003","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1242\/jcs.100.3.409","article-title":"Regulation of p34cdc2 protein kinase: new insights into protein phosphorylation and the cell cycle","volume":"100","author":"PR Clarke","year":"1991","journal-title":"J Cell Sci"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4161\/cc.3.1.595","article-title":"Many fingers on the mitotic trigger: post-translational regulation of the Cdc25C phosphatase","volume":"3","author":"JR Hutchins","year":"2004","journal-title":"Cell Cycle"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1073\/pnas.80.10.2926","article-title":"Monoclonal antibodies to mitotic cells","volume":"80","author":"FM Davis","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1134\/S0006297915110012","article-title":"Mechanisms of Apoptosis","volume":"80","author":"MA Savitskaya","year":"2015","journal-title":"Biochemistry (Mosc)"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","article-title":"Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification","volume":"95","author":"P le Coutre","year":"2000","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"ME Gorre","year":"2001","journal-title":"Science"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations","volume":"108","author":"HA Bradeen","year":"2006","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"34227","DOI":"10.1074\/jbc.M402290200","article-title":"A Bcr\/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2","volume":"279","author":"Y Dai","year":"2004","journal-title":"J Biol Chem"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/leu.2008.95","article-title":"Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells","volume":"22","author":"E Bonhoure","year":"2008","journal-title":"Leukemia"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0145-2126(00)00010-2","article-title":"The inhibition of ERK\/MAPK not the activation of JNK\/SAPK is primarily required to induce apoptosis in chronic myelogenous leukemic K562 cells","volume":"24","author":"CD Kang","year":"2000","journal-title":"Leuk Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"MW Deininger","year":"2000","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1158\/1078-0432.CCR-08-2141","article-title":"Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation","volume":"15","author":"X Shi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.biopha.2012.10.017","article-title":"Dihydroartemisinin inhibits the Bcr\/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib","volume":"67","author":"J Lee","year":"2013","journal-title":"Biomed Pharmacother"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/jcb.240580206","article-title":"Cell cycle and apoptosis: common pathways to life and death","volume":"58","author":"KL King","year":"1995","journal-title":"J Cell Biochem"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"30777","DOI":"10.1074\/jbc.273.46.30777","article-title":"Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest","volume":"273","author":"CD Scatena","year":"1998","journal-title":"J Biol Chem"},{"key":"ref34","first-page":"1935","article-title":"Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs","volume":"62","author":"JG Chen","year":"2002","journal-title":"Cancer Res"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.bcp.2011.10.008","article-title":"Cdk1\/cyclin B plays a key role in mitotic arrest-induced apoptosis by phosphorylation of Mcl-1, promoting its degradation and freeing Bak from sequestration","volume":"83","author":"R Chu","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1242\/jcs.073643","article-title":"Regulation of the Apaf-1-caspase-9 apoptosome","volume":"123","author":"SB Bratton","year":"2010","journal-title":"J Cell Sci"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1111\/bph.12431","article-title":"Cell death and the mitochondria: therapeutic targeting of the BCL-2 family-driven pathway","volume":"171","author":"MJ Roy","year":"2014","journal-title":"Br J Pharmacol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"7770","DOI":"10.1074\/jbc.273.13.7770","article-title":"The overexpression of Bax produces cell death upon induction of the mitochondrial permeability transition","volume":"273","author":"JG Pastorino","year":"1998","journal-title":"J Biol Chem"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/sj.cdd.4400889","article-title":"Bax translocation to mitochondria subsequent to a rapid loss of mitochondrial membrane potential","volume":"8","author":"SS Smaili","year":"2001","journal-title":"Cell Death Diff"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ccr.2005.06.012","article-title":"Killing cancer cells by flipping the Bcl-2\/Bax switch","volume":"8","author":"S Cory","year":"2005","journal-title":"Cancer Cell"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0145-2126(97)00006-4","article-title":"Bcl-2 and c-Myc expression, cell cycle kinetics and apoptosis during the progression of chronic myelogenous leukemia from diagnosis to blastic phase","volume":"21","author":"H Handa","year":"1997","journal-title":"Leuk Res"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1084\/jem.191.6.977","article-title":"Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL","volume":"191","author":"M Horita","year":"2000","journal-title":"J Exp Med"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1182\/blood-2004-02-0749","article-title":"Identification of mcl-1 as a BCR\/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides","volume":"105","author":"KJ Aichberger","year":"2005","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0186531","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T00:00:00Z","timestamp":1507680000000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0148093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T15:00:55Z","timestamp":1654182055000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0148093"}},"subtitle":[],"editor":[{"given":"Persio","family":"Dello Sbarba","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,1,27]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,1,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0148093","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,27]]}}}